BioPharma Resources

Drugs by condition

Drugs approved for ulcerative colitis

Brand-name prescription drugs and biologics whose FDA label lists ulcerative colitis as an approved use. Matched on the label phrases: "ulcerative colitis".

Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

59

Still marketed, NDA or BLA

Drug classes

8

Novel drugs

17

New molecular entities and new biologics

In development

40+

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for ulcerative colitis.

  • Starjemza (Ustekinumab-Hmny) · Bio-Thera Solutions LTD May 22, 2025
  • Otulfi (Ustekinumab-Aauz) · Fresenius Kabi USA Apr 30, 2025
  • Pyzchiva (Ustekinumab-Ttwe) · Samsung Bioepis CO LTD Apr 30, 2025
  • Steqeyma (Ustekinumab-Stba) · Celltrion, Inc. Dec 17, 2024
  • Imuldosa (Ustekinumab-Srlf) · Accord Biopharma Inc. Oct 10, 2024

All approved drugs for ulcerative colitis, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 198 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Interleukin-12 Antagonist (9)

  • Stelara Ustekinumab · Centocor Ortho Biotech INC · 2009
  • Starjemza Ustekinumab-Hmny · Bio-Thera Solutions LTD · 2025
  • Otulfi Ustekinumab-Aauz · Fresenius Kabi USA · 2025
  • Pyzchiva Ustekinumab-Ttwe · Samsung Bioepis CO LTD · 2025
  • Steqeyma Ustekinumab-Stba · Celltrion, Inc. · 2024
  • Pyzchiva Ustekinumab-Ttwe · Samsung Bioepis CO LTD · 2024
  • Wezlana Ustekinumab-Auub · Amgen INC · 2023
  • Wezlana Ustekinumab-Auub · Amgen INC · 2023
  • Stelara Ustekinumab · Janssen Biotech · 2016

Tumor Necrosis Factor Blocker (9)

  • Simponi Golimumab · Centocor Ortho Biotech INC · 2009
  • Remicade Infliximab · Centocor INC · 1998
  • Yusimry Adalimumab-Aqvh · Emerge Bioscience Pte LTD · 2021
  • Avsola Infliximab-Axxq · Amgen INC · 2019
  • Hadlima Adalimumab-Bwwd · Samsung Bioepis CO LTD · 2019
  • Hyrimoz Adalimumab-Adaz · Sandoz INC · 2018
  • Renflexis Infliximab-Abda · Samsung Bioepis CO LTD · 2017
  • Amjevita Adalimumab-Atto · Amgen INC · 2016
  • Inflectra Infliximab-Dyyb · Celltrion INC · 2016

Corticosteroid (6)

  • Medrol Methylprednisolone · Pfizer · 1957
  • Uceris Budesonide · Salix · 2014
  • Uceris Budesonide · Salix · 2013
  • Cortenema Hydrocortisone · Ani Pharms · 1966
  • Kenalog-40 Triamcinolone Acetonide · Apothecon · 1965
  • Cortef Hydrocortisone · Pharmacia and Upjohn · 1952

Aminosalicylate (5)

  • Rowasa Mesalamine · Mylan Speciality Lp · 1987
  • Azulfidine En-Tabs Sulfasalazine · Pfizer · 1950
  • Apriso Mesalamine · Salix · 2008
  • Lialda Mesalamine · Takeda Pharms USA · 2007
  • Pentasa Mesalamine · Takeda Pharms USA · 1993

Interleukin-23 Antagonist (4)

  • Omvoh Mirikizumab-Mrkz · Eli Lilly and CO · 2023
  • Skyrizi Risankizumab-Rzaa · Abbvie INC · 2019
  • Tremfya Guselkumab · Janssen Biotech · 2017
  • Skyrizi Risankizumab-Rzaa · Abbvie INC · 2022

Janus Kinase Inhibitor (2)

  • Rinvoq Upadacitinib · Abbvie · 2019
  • Rinvoq Lq Upadacitinib · Abbvie · 2024

Integrin Receptor Antagonist (2)

  • Entyvio Vedolizumab · Takeda Pharms USA · 2014
  • Entyvio Vedolizumab · Takeda Pharms USA · 2023

Class not listed in FDA's data (22)

  • Velsipity Etrasimod Arginine · Pfizer · 2023
  • Zeposia Ozanimod Hydrochloride · Bristol · 2020
  • Xeljanz Tofacitinib Citrate · Pf Prism Cv · 2012
  • Humira Adalimumab · Abbvie INC · 2002
  • Dipentum Olsalazine Sodium · Mylan Spclt Viatris · 1990
  • Celestone Soluspan Betamethasone Acetate, Betamethasone Sodium Phosphate · Organon · 1965
  • Imuldosa Ustekinumab-Srlf · Accord Biopharma Inc. · 2024
  • Selarsdi Ustekinumab-Aekn · Alvotech USA INC · 2024
  • Simlandi Adalimumab-Ryvk · Alvotech USA INC · 2024
  • Idacio Adalimumab-Aacf · Fresenius Kabi USA · 2024
  • Zymfentra Infliximab-Dyyb · Celltrion · 2023
  • Yuflyma Adalimumab-Aaty · Celltrion · 2023
  • Xeljanz Tofacitinib Citrate · Pfizer · 2020
  • Hulio Adalimumab-Fkjp · Mylan Pharms INC · 2020
  • Abrilada Adalimumab-Afzb · Pfizer INC · 2019
  • Cyltezo Adalimumab-Adbm · Boehringer Ingelheim · 2017
  • Xeljanz Xr Tofacitinib Citrate · Pfizer · 2016
  • Orapred Odt Prednisolone Sodium Phosphate · Advanz Pharma · 2006
  • Pediapred Prednisolone Sodium Phosphate · Pai Holdings · 1986
  • Depo-Medrol Methylprednisolone Acetate · Pfizer · 1959
  • Solu-Medrol Methylprednisolone Sodium Succinate · Pharmacia and Upjohn · 1959
  • Solu-Cortef Hydrocortisone Sodium Succinate · Pharmacia and Upjohn · 1955

Drugs in development for ulcerative colitis

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • ZasocitinibTAK- 279, NDI-034858Phase 317 trials

    Takeda · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease

  • AfimkibartRO7790121, RVT-3101Phase 312 trials

    Roche (Genentech) · Moderately to Severely Active Ulcerative Colitis, Moderately to Severely Active Crohns Disease, Atopic Dermatitis

  • MK-7240PRA023, TulisokibartPhase 310 trials

    Merck & Co. · Ulcerative Colitis, Psoriatic Arthritis, Crohn's Disease

  • LutikizumabABT-981Phase 38 trials

    AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis

  • DuvakitugSAR447189, TEV-48574 APhase 36 trials

    Sanofi · Ulcerative Colitis, Crohn's Disease, Hidradenitis

  • FilgotinibGS-6034, GLPG0634Phase 36 trials

    Alfasigma S.p.A. · Ulcerative Colitis, Polyarticular Course Juvenile Idiopathic Arthritis, Juvenile Idiopathic Arthritis (JIA)

  • ABX464ObefazimodPhase 35 trials

    Abivax S.A. · Ulcerative Colitis, Moderately to Severely Active Crohn Disease

  • Hemay005Mufemilast, Phosphodiesterase 4 inhibitorsPhase 34 trials

    Ganzhou Hemay Pharmaceutical Co., Ltd · Moderate to Severe Ulcerative Colitis, Ulcerative Colitis (UC), COPD (Chronic Obstructive Pulmonary Disease)

  • brivekimigSAR442970Phase 25 trials

    Sanofi · Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion, Type 1 Diabetes Mellitus

  • SHR-1139Phase 25 trials

    Guangdong Hengrui Pharmaceutical Co., Ltd · Moderate to Severe Plaque Psoriasis, Palmoplantar Pustulosis of Adults, Pyoderma Gangrenosum

  • MORF-057zotemtegrast, LY4268989Phase 24 trials

    Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) · Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis (UC)

  • IPG11406Phase 23 trials

    Nanjing Immunophage Biotech Co., Ltd · Lupus Nephritis, Moderately to Severely Active Ulcerative Colitis (UC)

  • ABBV-701Phase 22 trials

    AbbVie · Crohn's Disease, Ulcerative Colitis, Psoriatic Arthritis

  • Biocad · Ulcerative Colitis (UC), Crohn's Disease (CD)

  • EltrekibartLY3041658Phase 22 trials

    Eli Lilly · Ulcerative Colitis, Ulcerative Colitis Chronic, Hidradenitis Suppurativa

  • HSK47388Phase 22 trials

    Haisco Pharmaceutical Group Co., Ltd. · Plaque Psoriasis, Ulcerative Colitis (UC)

  • RosnilimabANB030Phase 22 trials

    AnaptysBio, Inc. · Rheumatoid Arthritis, Ulcerative Colitis

  • SPY001SPY001-001Phase 22 trials

    Spyre Therapeutics, Inc. · Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis

  • SPY002SPY002-091Phase 22 trials

    Spyre Therapeutics, Inc. · Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis

  • SPY003SPY003-207Phase 22 trials

    Spyre Therapeutics, Inc. · Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis

More on ulcerative colitis: recruiting trials · published research

Related in immunology and inflammation: Rheumatoid arthritis · Plaque psoriasis · Psoriatic arthritis · Atopic dermatitis (eczema) · Crohn's disease · Ankylosing spondylitis · Lupus (SLE) · Hidradenitis suppurativa · Chronic hives (urticaria) · Alopecia areata

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.